Risks and Benefits of Statin Use in Young People with Type 1 Diabetes

Macrovascular Complications in Diabetes (L Perreault, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Macrovascular Complications in Diabetes


Cardiovascular disease (CVD) is the primary cause of mortality in patients with type 1 diabetes (T1D). Despite advances in the management of microvascular complications of T1D, there is a lack of similar progress in reduction of macrovascular complications. Dyslipidemia is one of the major contributory factors for macrovascular complications in T1D, but the literature suggests significant under-treatment of this risk factor in children and adolescents with diabetes. Statins have shown to be both effective and safe in young people with familial hypercholesterolemia and adults with diabetes mellitus, but the role for statins in children and adolescent with T1D remains unclear and controversial. In this review, we will summarize the risks and benefits of statin use in young people with T1D.


Dyslipidemia Type 1 diabetes Statins Lipid-lowering medications Macrovascular complications Microvascular complications 


Compliance with Ethics Guidelines

Conflict of Interest

Petter Bjornstad and R. Paul Wadwa declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Soltesz G, Patterson CC, Dahlquist G. Worldwide childhood type 1 diabetes incidence–what can we learn from epidemiology? Pediatr Diabetes. 2007;8 Suppl 6:6–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Federation ID. Diabetes. Atlas. 2007.Google Scholar
  3. 3.
    Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation. 2005;111:3489–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D. Kordonouri et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care. 2006;29:218–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Margeirsdottir HD, Larsen JR, Brunborg C, Overby NC, Dahl-Jorgensen K. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia. 2008;51:554–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Maahs DM, Rewers M. Editorial: mortality and renal disease in type 1 diabetes mellitus–progress made, more to be done. J Clin Endocrinol Metab. 2006;91:3757–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55:1463–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman III WP, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281:727–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Berenson GS, Srinivasan SR, Bao W, Newman III WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Reiner Z. Statins in the primary prevention of cardiovascular disease. Nature reviews. Cardiology. 2013;10:453–64.PubMedGoogle Scholar
  12. 12.
    Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Kershnar AK, Daniels SR, Imperatore G, Palla SL, Petitti DB, Pettitt DJ, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr. 2006;149:314–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ. 1970;43:891–915.PubMedGoogle Scholar
  15. 15.
    Maahs DM, Wadwa RP, McFann K, Nadeau K, Williams MR, Eckel RH, et al. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes. J Pediatr. 2007;150:146–50. 150e, 141–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Daneman D. Early diabetes-related complications in adolescents: risk factors and screening. Horm Res. 2005;63:75–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001;104:2815–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290:2277–83.PubMedCrossRefGoogle Scholar
  19. 19.
    McGill Jr HC, McMahan CA. Starting earlier to prevent heart disease. JAMA. 2003;290:2320–2.PubMedCrossRefGoogle Scholar
  20. 20.
    2013 Standards of medical care in diabetes. Diabetes Care. 2013;36(Suppl 1):S11–66.Google Scholar
  21. 21.
    Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes. 2009;10 Suppl 12:195–203.PubMedCrossRefGoogle Scholar
  22. 22.
    Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006;114:1056–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. National Heart Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213–56.Google Scholar
  24. 24.
    Maahs DM, Wadwa RP, Bishop F, Daniels SR, Rewers M, Klingensmith GJ. Dyslipidemia in youth with diabetes: to treat or not to treat? J Pediatr. 2008;153:458–65.Google Scholar
  25. 25.
    Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedCrossRefGoogle Scholar
  28. 28.
    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–64.Google Scholar
  29. 29.
    Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156(231–6):e231–3.CrossRefGoogle Scholar
  30. 30.
    Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes xObes Metab. 2010;12:384–92.CrossRefGoogle Scholar
  31. 31.
    Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, et al. Insulin resistance in adolescents with type 1 diabetes. and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010;95:513–21.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    O'Gorman CS, O'Neill MB, Conwell LS. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2011;7:1–14.PubMedCentralGoogle Scholar
  33. 33.
    Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child. 1985;60:34–7.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol. 2001;87:1174–80. A1174.PubMedCrossRefGoogle Scholar
  35. 35.
    McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115:1948–67.PubMedCrossRefGoogle Scholar
  36. 36.
    Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208.PubMedCrossRefGoogle Scholar
  37. 37.
    Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007;71:1215–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007;119:370–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi: 10.1016/j.jacc.2013.11.002.
  40. 40.
    Raymond C, Cho L, Rocco M, Hazen SL. New cholesterol guidelines: worth the wait? Cleve Clin J Med. 2014;81:11–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Lambert M, Lupien PJ, Gagne C, Levy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics. 1996;97:619–28.PubMedGoogle Scholar
  42. 42.
    Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39:867–71.PubMedCrossRefGoogle Scholar
  43. 43.
    McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Jarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimaki T, Solakivi T, Ronnemaa T, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes. 2002;51:493–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664–8.PubMedCrossRefGoogle Scholar
  48. 48.
    de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117–21.PubMedCrossRefGoogle Scholar
  49. 49.•
    Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, Pepine C, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2009;22:65–8. This study provides evidence of the efficacy and safety of statins in adolescents with T1D.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Canas JA. Atorvastatin safely reduced non-HDL cholesterol in children with type 1 diabetes (T1DM) and high LDL-C: preliminary results. Endocrine Rev. 2013; 39, online supplement, abstract OR11–2.Google Scholar
  51. 51.
    Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010;126:e225–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRefGoogle Scholar
  53. 53.
    Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.PubMedCrossRefGoogle Scholar
  54. 54.
    Kwiterovich Jr PO. State-of-the-art update and review: clinical trials of lipid-lowering agents. Am J Cardiol. 1998;82:3U–17U. discussion 39U–41U.PubMedCrossRefGoogle Scholar
  55. 55.
    Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.PubMedCrossRefGoogle Scholar
  56. 56.
    Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.PubMedCrossRefGoogle Scholar
  57. 57.
    Schwab KO, Doerfer J, Marg W, Schober E, Holl RW. Characterization of 33 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. Pediatr Diabetes. 2010;11:357–63.PubMedCrossRefGoogle Scholar
  58. 58.
    Maahs DM, Ogden LG, Dabelea D, Snell-Bergeon JK, Daniels SR, Hamman RF, et al. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia. 2010;53:2518–25.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.•
    Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case–control study. Diabetes Care. 2009;32:416–20. This study reports abnormal lipid levels in adoelscents with T1D and good glycemic control, even after a relatively short disease duration.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Lauer RM, Obarzanek E, Hunsberger SA, Van Horn L, Hartmuller VW, Barton BA, et al. Efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL cholesterol: the Dietary Intervention Study in Children. Am J Clin Nutr. 2000;72:1332S–42S.PubMedGoogle Scholar
  61. 61.
    Mayer-Davis EJ, Nichols M, Liese AD, Bell RA, Dabelea DM, Johansen JM, et al. Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc. 2006;106:689–97.PubMedCrossRefGoogle Scholar
  62. 62.
    Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26:2653–64.PubMedCrossRefGoogle Scholar
  63. 63.
    Trotta D, Verrotti A, Salladini C, Chiarelli F. Diabetic neuropathy in children and adolescents. Pediatr Diabetes. 2004;5:44–57.PubMedCrossRefGoogle Scholar
  64. 64.
    Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000;26:254–64.PubMedGoogle Scholar
  65. 65.
    Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Elliott J, Tesfaye S, Chaturvedi N, Gandhi RA, Stevens LK, Emery C, et al. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care. 2009;32:1896–900.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1–11.PubMedCrossRefGoogle Scholar
  68. 68.
    Elisaf M, Mikhailidis DP. Statins and renal function. Angiology. 2002;53:493–502.PubMedCrossRefGoogle Scholar
  69. 69.
    Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabet Complicat. 2001;15:113–9.CrossRefGoogle Scholar
  70. 70.
    Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract. 2005;68 Suppl 2:S3–S14.PubMedCrossRefGoogle Scholar
  71. 71.
    de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Stein EA, Illingworth DR, Kwiterovich Jr PO, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999;281:137–44.PubMedCrossRefGoogle Scholar
  73. 73.
    Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2010;7(7):CD006401. doi: 10.1002/14651858.CD006401.pub2.
  74. 74.•
    Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013. Important report of increased risk of cataracts with statin use. Google Scholar
  75. 75.
    Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedCrossRefGoogle Scholar
  76. 76.
    Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61:148–52.PubMedCrossRefGoogle Scholar
  77. 77.
    Kusters DM, Homsma SJ, Hutten BA, Twickler MT, Avis HJ, van der Post JA, et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. Neth J Med. 2010;68:299–303.PubMedGoogle Scholar
  78. 78.
    Krantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. J Pediatr. 2004;145:452–7.PubMedCrossRefGoogle Scholar
  79. 79.
    McGill Jr HC, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation. 2001;103:1546–50.PubMedCrossRefGoogle Scholar
  80. 80.
    Tunstall-Pedoe H. Starting statins for primary prevention of cardiovascular disease. Heart. 2013;99(21):1547–8.Google Scholar
  81. 81.•
    Wood JR, Miller KM, Maahs DM, Beck RW, Dimeglio LA, Libman IM, et al. Most youth with type 1 diabetes. in the T1D exchange clinic registry do not meet American diabetes. Association or International Society for Pediatric and Adolescent Diabetes. Clinical Guidelines. Diabetes Care. 2013;36:2035–7. Important report from T1D Exchange Clinic Registry showing that most adolescents with T1D do not meet ADA's recommendations for LDL-C.PubMedCentralPubMedCrossRefGoogle Scholar
  82. 82.
    Bishop FK, Wadwa RP, Ellis S, Rewers M, Maahs DM. Lessons learned from a lipid lowering trial in adolescents with type 1 diabetes. Int J Pediatr Endocrinol. 2012;2012:24.PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Adolescent type 1 Diabetes. Cardio-renal Intervention Trial (AdDIT). BMC Pediatr. 2009;9:79.Google Scholar
  84. 84.•
    Marcovecchio ML, Woodside J, Jones T, Daneman D, Neil A, Prevost T, et al. Adolescent Type 1 Diabetes cardio-renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care. 2014;37:805–13. The first baseline paper for the AdDIT study. Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Colorado School of MedicineAuroraUSA
  2. 2.Barbara Davis Center for Childhood DiabetesUniversity of Colorado, DenverAuroraUSA

Personalised recommendations